01.09.08
Dan Brazier has been appointed president and chief executive officer of Draxis Health, Inc. and Jean-Pierre Robert was named chief operating officer. Mr. Robert will retain his position as president of Draxis Specialty Pharmaceuticals, Inc. (DSP).
Brian King, chair of the board of directors, said, "The board of directors has full confidence that the streamlined executive management team under Dan Brazier's leadership has the capabilities to deliver on its strategic plan for the company that positions Draxis for significant growth beginning in 2008 and extending into the future. Recently announced partnerships, new business activities and the continuing development of several significant new products that are expected to be introduced over the next several years represent significant opportunities for value creation."
The company was looking for a successor to Dr. Martin Barkin, who retired as president and chief executive officer December 31, 2007.
Mr. Brazier joined the company's executive management team in 1998, was named chief operating officer in October 2005, and since July 2007 he served in the office of the president with Dr. Barkin. Mr. Brazier also held the positions of senior vice president, corporate development and strategic planning, and president of the Canadian pharmaceutical sales and marketing division of Draxis Health. He has 30 years of business experience with several consumer marketing, healthcare and pharmaceutical companies in a variety of roles of increasing responsibility.
Mr. Robert joined the company in April 2005 as president of the radiopharmaceuticals business unit in Montreal and as a member of the executive management team. In July 2007 he became president of Draxis Specialty Pharmaceuticals, Inc., responsible for both DRAXIMAGE, the division of DSP that makes radiopharmaceutical products and for Draxis Pharma, the contract manufacturing division of DSP, which produces sterile and non-sterile products for clients in the pharma/biopharma sectors. Before joining the company, Mr. Robert spent several years with Tyco Healthcare (Canada), now Covidien Ltd., most recently as vice president and general manager, where he oversaw domestic and export operations including marketing, sales, finance, and contract manufacturing operations. Mr. Robert also served as president and chief executive officer of an emerging Canadian biopharmaceutical company.
Brian King, chair of the board of directors, said, "The board of directors has full confidence that the streamlined executive management team under Dan Brazier's leadership has the capabilities to deliver on its strategic plan for the company that positions Draxis for significant growth beginning in 2008 and extending into the future. Recently announced partnerships, new business activities and the continuing development of several significant new products that are expected to be introduced over the next several years represent significant opportunities for value creation."
The company was looking for a successor to Dr. Martin Barkin, who retired as president and chief executive officer December 31, 2007.
Mr. Brazier joined the company's executive management team in 1998, was named chief operating officer in October 2005, and since July 2007 he served in the office of the president with Dr. Barkin. Mr. Brazier also held the positions of senior vice president, corporate development and strategic planning, and president of the Canadian pharmaceutical sales and marketing division of Draxis Health. He has 30 years of business experience with several consumer marketing, healthcare and pharmaceutical companies in a variety of roles of increasing responsibility.
Mr. Robert joined the company in April 2005 as president of the radiopharmaceuticals business unit in Montreal and as a member of the executive management team. In July 2007 he became president of Draxis Specialty Pharmaceuticals, Inc., responsible for both DRAXIMAGE, the division of DSP that makes radiopharmaceutical products and for Draxis Pharma, the contract manufacturing division of DSP, which produces sterile and non-sterile products for clients in the pharma/biopharma sectors. Before joining the company, Mr. Robert spent several years with Tyco Healthcare (Canada), now Covidien Ltd., most recently as vice president and general manager, where he oversaw domestic and export operations including marketing, sales, finance, and contract manufacturing operations. Mr. Robert also served as president and chief executive officer of an emerging Canadian biopharmaceutical company.